Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Sethi V, Rubinstein I, Kuzmis A, Kastrissios H, Artwohl J, Onyuksel H.

Mol Pharm. 2013 Feb 4;10(2):728-38. doi: 10.1021/mp300539f. Epub 2013 Jan 23.

PMID:
23211088
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis.

Koo OM, Rubinstein I, Onyüksel H.

Pharm Res. 2011 Apr;28(4):776-87. doi: 10.1007/s11095-010-0330-4. Epub 2010 Dec 4.

PMID:
21132352
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease.

Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP.

Nat Med. 2001 May;7(5):563-8.

PMID:
11329057
[PubMed - indexed for MEDLINE]
4.

Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis.

Juarranz Y, Abad C, Martinez C, Arranz A, Gutierrez-Cañas I, Rosignoli F, Gomariz RP, Leceta J.

Arthritis Res Ther. 2005;7(5):R1034-45. Epub 2005 Jun 23.

PMID:
16207319
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1-38) in pegylated phospholipid micelles.

Ashok B, Rubinstein I, Tsueshita T, Onyüksel H.

Peptides. 2004 Aug;25(8):1253-8.

PMID:
15350692
[PubMed - indexed for MEDLINE]
6.

A novel peptide nanomedicine for treatment of pancreatogenic diabetes.

Banerjee A, Onyuksel H.

Nanomedicine. 2013 Aug;9(6):722-8. doi: 10.1016/j.nano.2012.12.005. Epub 2013 Jan 22.

PMID:
23347897
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Conformation and vasoreactivity of VIP in phospholipids: effects of calmodulin.

Rubinstein I, Patel M, Ikezaki H, Dagar S, Onyüksel H.

Peptides. 1999 Dec;20(12):1497-501.

PMID:
10698126
[PubMed - indexed for MEDLINE]
8.

VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.

Onyüksel H, Mohanty PS, Rubinstein I.

Int J Pharm. 2009 Jan 5;365(1-2):157-61. doi: 10.1016/j.ijpharm.2008.08.024. Epub 2008 Aug 27.

PMID:
18793708
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.

Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E, Martin J.

Arthritis Rheum. 2008 Apr;58(4):1010-9. doi: 10.1002/art.23482.

PMID:
18383379
[PubMed - indexed for MEDLINE]
Free Article
10.

Liposomal vasoactive intestinal peptide.

Sethi V, Onyüksel H, Rubinstein I.

Methods Enzymol. 2005;391:377-95.

PMID:
15721392
[PubMed - indexed for MEDLINE]
11.

Micellar nanomedicine of human neuropeptide Y.

Kuzmis A, Lim SB, Desai E, Jeon E, Lee BS, Rubinstein I, Onyüksel H.

Nanomedicine. 2011 Aug;7(4):464-71. doi: 10.1016/j.nano.2011.01.004. Epub 2011 Jan 25.

PMID:
21272667
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases.

Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J.

J Mol Med (Berl). 2002 Jan;80(1):16-24. Epub 2001 Oct 17. Review.

PMID:
11862320
[PubMed - indexed for MEDLINE]
13.

In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.

Delgado M, Toscano MG, Benabdellah K, Cobo M, O'Valle F, Gonzalez-Rey E, Martín F.

Arthritis Rheum. 2008 Apr;58(4):1026-37. doi: 10.1002/art.23283.

PMID:
18383372
[PubMed - indexed for MEDLINE]
Free Article
14.

Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis.

Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M.

Arthritis Rheum. 2006 Mar;54(3):864-76.

PMID:
16508968
[PubMed - indexed for MEDLINE]
Free Article
15.

A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles.

Lim SB, Rubinstein I, Sadikot RT, Artwohl JE, Önyüksel H.

Pharm Res. 2011 Mar;28(3):662-72. doi: 10.1007/s11095-010-0322-4. Epub 2010 Nov 25.

PMID:
21108040
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension.

Onyüksel H, Séjourné F, Suzuki H, Rubinstein I.

Peptides. 2006 Sep;27(9):2271-5. Epub 2006 Apr 18.

PMID:
16621151
[PubMed - indexed for MEDLINE]
17.

Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.

Rubinstein I, Weinberg GL.

Nanomedicine. 2012 Sep;8 Suppl 1:S77-82. doi: 10.1016/j.nano.2012.05.004. Epub 2012 May 26. Review.

PMID:
22640912
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo.

Onyüksel H, Ikezaki H, Patel M, Gao XP, Rubinstein I.

Pharm Res. 1999 Jan;16(1):155-60.

PMID:
9950295
[PubMed - indexed for MEDLINE]
19.

Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells.

Gülçür E, Thaqi M, Khaja F, Kuzmis A, Onyüksel H.

Drug Deliv Transl Res. 2013 Dec;3(6). doi: 10.1007/s13346-013-0167-6.

PMID:
24363979
[PubMed]
20.

Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.

Rubinstein I, Weinberg GL.

Maturitas. 2012 Sep;73(1):68-73. doi: 10.1016/j.maturitas.2011.11.021. Epub 2012 Jan 20. Review.

PMID:
22264497
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk